Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110] Draft guidance Technology appraisal guidance 27 March ...

While annual physical checks already take place for people with long-term conditions, we've found that BMI and waist-to-height measurements aren't consistently recorded. Our new approach addresses ...

For further information on how we select topics for development, please see our page about topic selection ...

Suggested remit: To appraise the clinical and cost effectiveness of vosoritide within its marketing authorisation for treating achondroplasia in people 4 months and over.

Further information The 2024 voluntary scheme for branded medicines, pricing, access and growth states that NICE will continue to evaluate all new active substances and significant indications, except ...

Further information The NICE-Wide Prioritisation Board and NHS England have agreed that a Technology Appraisal (TA) would not be appropriate for this product and recommended that it is not selected ...

Please note that following on from information provided to NICE by the company in February 2024 the appraisal was suspended from NICE’s work programme. As no further information has been received from ...

A list of downloadable documents created during development.

NICE guidance published today recommends leniolisib (also called Joenja and made by Pharming) for treating activated phosphoinositide 3-kinase delta syndrome (APDS) in people 12 years and over.

The treatment, called relugolix–estradiol–norethisterone (also known as relugolix combination therapy or Ryeqo), works by blocking specific hormones that contribute to endometriosis, while also ...